BDNF

DGAP-News: BLACKHAWK GROWTH'S MINDBIO THERAPEUTICS LOOKS TO EXPAND MICRODOSING CLINICAL TRIALS

Retrieved on: 
Monday, November 1, 2021
DGAP, BLR, DMT, Black Hawk, Technology, Cannabis, University, Anxiety, CSE, Patient, BDNF, SEDAR, Psilocybin, PTSD, LSD, Company, Investment, Mental health, Clinical trial, Intention, CEO, Lysergic acid diethylamide, University of California, San Francisco, Health, Space food, Therapy, News, Acquisition, Lysergic acid, Lists of diseases, Security (finance), Pharmaceutical industry

Vancouver, British Columbia - November 01, 2021 - Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the "Corporation" or "Blackhawk"), is pleased to announce that MindBio Therapeutics Pty Ltd ("MindBio") is working to expand its microdosing clinical trials.

Key Points: 
  • Vancouver, British Columbia - November 01, 2021 - Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the "Corporation" or "Blackhawk"), is pleased to announce that MindBio Therapeutics Pty Ltd ("MindBio") is working to expand its microdosing clinical trials.
  • In its phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide), MindBio is microdosing LSD to 80 healthy participants who take the drug at home in the same way that they would take any other medication.
  • MindBio will lead phase 2 clinical trials microdosing LSD to patients with major depressive disorder and in patients with late-stage cancer - with those trials set to begin in mid-2022.
  • MindBio is currently assessing natural psilocybin and potential analogs as a candidate for phase 1 microdosing clinical trials.

Fresh Bros: Exploring the Top Five Health Benefits of Turmeric Extract with BioPerine

Retrieved on: 
Wednesday, October 27, 2021
People, Woman, Depression, Arthritis, Degenerative disease, Neuron, Allergy, Herbal, Infection, BDNF, Time-invariant system, Osteoarthritis, Athlete, Piperine, Brain, Curcumin, Oxidative stress, Absorption, Ageing, Growth, Chemistry (relationship), Stroke, Farm, Cell, Laboratory, Rheumatoid arthritis, GLOBE, Medicinal plants, Spice, Dietary supplement

Fresh Bros now stock Turmeric (Curcumin) Extract with BioPerine .

Key Points: 
  • Fresh Bros now stock Turmeric (Curcumin) Extract with BioPerine .
  • BioPerine is a patented piperine extract, containing at least 95% piperine in a form that is readily absorbed by your body.
  • Fresh Bros put this in their turmeric extract to improve the bioavailability and absorption of the turmeric so you get the full benefit of this wonderful spice.
  • Fresh Bros sells the freshest organically grown hemp and CBD wholesale products from USA farms and laboratories, including turmeric (curcumin) extract with BioPerine.

Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting

Retrieved on: 
Wednesday, October 27, 2021
Research, University, SAN, Assistant, GJB2, Hearing, Tropomyosin receptor kinase B, Hearing loss, University of South Florida, BDNF, Patient, Neurotology, Society, Tropomyosin receptor kinase C, Review, M3, Ear, Tinnitus, EST, Â, Therapy, GLOBE, SFN, Congenital hearing loss, Applied Genetic Technologies Corporation, Pharmaceutical industry

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc.(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Neuroscience 2021 meeting, which is the annual meeting of the Society for Neuroscience (SfN).

Key Points: 
  • SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc.(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Neuroscience 2021 meeting, which is the annual meeting of the Society for Neuroscience (SfN).
  • This meeting will be held virtually November 8-11, 2021 with Preview Days taking place November 3-7 during which registered attendees can preview pre-recorded presentations.
  • Otonomys presentations include the previously disclosed positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss, and multiple presentations related to Otonomys preclinical programs.
  • All other Otonomy presentations are during interactive poster sessions occurring from 3:30 to 4:30 p.m. EST on November 10.

Mitochon Pharmaceuticals and University of Kentucky Awarded MTEC Grant for MP-201 in Traumatic Brain Injury

Retrieved on: 
Tuesday, September 28, 2021
Research, Philanthropy, Pharmaceutical, Medical Devices, University, Fund Raising, Education, Foundation, Clinical Trials, Science, Biotechnology, FDA, Health, Mitochondrion, Trauma, BDNF, Frasier, Research, Exercise, Biomedical technology, Injury, Degenerative disease, OTA, Patient, MTEC, Disorder, Medication, University, Fasting, Concussion, Blunt trauma, BrightFocus Foundation, MP101, Life, United States Army Medical Research and Development Command, TBI, Disease, Cognition, Traumatic brain injury, IND, ALS, Macular degeneration, Neuromuscular junction, Glaucoma, Dementia, Doctor of Philosophy, Neurodegeneration, Treatment, Bureau of Oceans and International Environmental and Scientific Affairs, Neuron, Pharmaceutical industry, Vaccine, Medical device, Mitochon Pharmaceuticals, MTEC, BrightFocus Foundation, MITOCHON PHARMACEUTICALS, MTEC, BRIGHTFOCUS FOUNDATION

We are delighted to receive his prestigious award with the University of Kentucky and look forward to building the dossier for MP-201 a mitochondrial targeting compound in Traumatic Brain Injury.

Key Points: 
  • We are delighted to receive his prestigious award with the University of Kentucky and look forward to building the dossier for MP-201 a mitochondrial targeting compound in Traumatic Brain Injury.
  • We are very excited about the potential of MP-201 as our research clearly shows a link between mitochondrial dysfunction and TBI.
  • Our previous research indicates that mitochondrial impairment is a key mediator of worsened response to repeated mild head impacts.
  • These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition and neural growth.

Gundry MD™ Launches Active Advantage

Retrieved on: 
Thursday, August 26, 2021
Center, Fatigue, Alertness, ATP, Ageing, Endurance, Polyphenol, Mitochondrion, Organic acid, Antioxidant, Thought, Memory, Research, Health, Metabolism, Steven Gundry, Time, Cell, Lectin, Tocotrienol, Nutrient, Protein, Coenzyme Q10, Digestion, Longevity, Astaxanthin, BDNF, Medical device, Dietary supplement

LOS ANGELES, Aug. 26, 2021 /PRNewswire/ -- Active Advantage by Gundry MD is an energy enhancement blend designed to help promote physical and mental energy.

Key Points: 
  • LOS ANGELES, Aug. 26, 2021 /PRNewswire/ -- Active Advantage by Gundry MD is an energy enhancement blend designed to help promote physical and mental energy.
  • Gundry MD Active Advantage is a revolutionary antioxidant blend designed to help the body support energy levels, strength, and metabolism.
  • Also, he is the founder of Gundry MD, a line of wellness products, and host of The Dr. Gundry Podcast.
  • Trial users of Gundry MD Active Advantage reported results within the first 7 days of use, and even more dramatic results over time.